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Defects in the innate immune system in the lung with attendant
bacterial infections contribute to lung tissue damage, respiratory
insufficiency, and ultimately death in the pathogenesis of cystic
fibrosis (CF). Professional phagocytes, including alveolar macrophages
(AMs), have specialized pathways that ensure efficient killing of
pathogens in phagosomes. Phagosomal acidification facilitates the
optimal functioning of degradative enzymes, ultimately contributing
to bacterial killing. Generation of low organellar pH is primarily
driven by the V-ATPases, proton pumps that use cytoplasmic ATP to
load H+ into the organelle. Critical to phagosomal acidification are
various channels derived from the plasma membrane, including the
anion channel cystic fibrosis transmembrane conductance regulator,
which shunt the transmembrane potential generated by movement
of protons. Here we show that the transient receptor potential ca-
nonical-6 (TRPC6) calcium-permeable channel in the AM also functions
to shunt the transmembrane potential generated by proton pumping
and is capable of restoringmicrobicidal function to compromised AMs
in CF and enhancement of function in non-CF cells. TRPC6 channel
activity is enhanced via translocation to the cell surface (and then
ultimately to the phagosome during phagocytosis) in response to
G-protein signaling activated by the small molecule (R)-roscovitine
and its derivatives. These data show that enhancing vesicular inser-
tion of the TRPC6 channel to the plasma membrane may represent a
general mechanism for restoring phagosome activity in conditions,
where it is lost or impaired.
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Chronic infection and inflammation in the airways in cysticfibrosis (CF), as well as chronic obstructive pulmonary disease
(COPD), tuberculosis, and asthma are now among the most com-
mon chronic diseases. Pulmonary infection associated with these
diseases has historically been treated with antibiotics that kill
bacteria but also select for development of resistance in the path-
ogen in the chronically infected lung (1, 2). One solution to anti-
microbial drug resistance is to target the host rather than the
pathogen. This strategy necessitates finding alternative targets or
signaling strategies amplifying or restoring bactericidal capacity in
the cells charged with the task of resolving chronic infection.
Mononuclear phagocytes orchestrate the innate immune response
in the lung through the combinatorial interplay between the phago-
cytic uptake and killing of bacterial invaders, clearance of apoptotic
cells, antigen presentation, and secretion of vesicle-bound signaling
molecules to recruit help in the resolution of infection. Ionic fluxes
across the phagosomal membrane that encloses the pathogen pro-
duce a hostile acidic environment developed through the action of a
V-ATPase proton translocation. However, a positive intraphagosomal
membrane potential generated by proton translocation minimizes
the proton content of the phagosome. An influx of Cl− via Cl−
channels reduces the membrane potential generated by the proton
pump, thereby, allowing maximal acidification of the phagolysosomal
compartment, which in turn maximizes the activation of lysosomal
degradative enzymes, generation of hypochlorous acid, and con-
sequent bacterial killing (3, 4). We have previously demonstrated
that murine alveolar macrophages (AMs) use the anion channel
cystic fibrosis transmembrane conductance regulator (CFTR) as
a Cl− permeation pathway in the phagosomal membrane. In CF,
loss of functional CFTR in the AM alkalinizes the phagosomal
lumen and allows antimicrobial-resistant bacterial pathogens to
survive macrophage surveillance.
Not all tissue macrophages use CFTR as a charge compensation
pathway in phagolysosomal acidification (4). In fact, recent data
suggest that multiple V-ATPase charge-shunt pathways can exist in
diverse macrophage lineages (5) via lysosomal recruitment and
Significance
Historically, pulmonary infections treated with antibiotics killed
bacteria while selecting for the unintended development of path-
ogenic resistance. One strategy to circumvent antibiotic resistance
in pulmonary infection involves targeting the host phagosome and
augmenting its function. To such an end, we have identified sev-
eral small molecules, (R)-roscovitine and its derivatives, which re-
storemicrobicidal activity to compromised alveolar macrophages in
cystic fibrosis (CF) and enhance function in non-CF cells. The com-
pounds utilize G protein signaling pathways that mobilize TRPC-6
channels to the plasmalemma and subsequent phagosomal mem-
brane formation that engulfs the bacterium. The plethora of GPCRs
in resident pulmonary macrophages linked to ion channel function
provides a rich source for potential therapeutic approaches
to macrophage-mediated disease.
Author contributions: V.R., A.G.G., V.P.B., and D.J.N. designed research; V.R., A.G.G., R.R.E.,
L.V.D., D.K.H., N.L., P.S., A.J.G., S.G.Y., and A.P.N. performed research; N.O., H.G., M.L.V., D.W.B.,
V.P.B., L.B., and L.M. contributed new reagents/analytic tools; V.R., A.G.G., L.S.B., R.R.E., L.V.D.,
N.L., M.E.B., and V.P.B. analyzed data; V.R., A.G.G., and D.J.N. wrote the paper; and L.B. gen-
erated and provided the TPRC6-deficient mice and experimental strategies for the Ca2+ exper-
iments, and contributed significant suggestions to manuscript, as well as figure design
and revisions.
Reviewers: M.E.E., Yale University School of Medicine; and E.G., University of Duisburg-
Essen.
Conflict of interest statement: L.M. is an employee and shareholder of ManRos Thera-
peutics. L.M. is a founder of ManRos Therapeutics and a member of its scientific advisory
board. L.M. is a co-inventor on the roscovitine patent. H.G. is a consultant for and share-
holder of ManRos Therapeutics. H.G. is a founder of ManRos Therapeutics and a member
of its scientific advisory board. N.O. is an employee of ManRos Therapeutics. N.L. is an
employee of the CNRS, funded on a grant from ManRos Therapeutics.
Freely available online through the PNAS open access option.
1V.R. and A.G.G. contributed equally to this work.
2To whom correspondence may be addressed. Email: Birnbau1@gmail.com or nelson@
uchicago.edu.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1518966112/-/DCSupplemental.
E6486–E6495 | PNAS | Published online November 10, 2015 www.pnas.org/cgi/doi/10.1073/pnas.1518966112
membrane insertion upon particle uptake. This observation led us
to search for possible alternative charge-shunt pathways in pulmo-
nary macrophages and how they might be activated or targeted
to the maturing phagosome. Could a pharmacological tool cir-
cumvent the defect in CF AMs and activate alternative pathways
to rescue both organellar acidification and bactericidal activity in
cells expressing mutations in CFTR? Such a tool might activate
parallel charge-shunt pathways used in peritoneal macrophages
for maximum acidification, thereby allowing them to clear bacteria
independently of CFTR expression as well as amplify the micro-
bicidal response in the presence of functional CFTR. The transport
proteins and channels active in peritoneal macrophage bacterial
clearance have not been described but may involve a K+/H+ ex-
changer important in promoting excitatory synaptic vesicle filling
(6) or a cation channel moving positive charge out of the phag-
olysosomal compartment, as has been suggested for macrophage
cell lines (7).
We began our investigations pursuing a novel pharmacological
strategy to identify compounds that would resolve bacterial in-
fection in the CF lung without the use of antimicrobials. We picked
a cellular defect in CF because of the availability of animal models
and extended our observations to non-CF human pulmonary cells.
We designed screening assays of phagosome function, which could
be used in a clinical setting as both diagnostic and investigational
tools. We interrogated host function by studying surface receptor-
mediated mechanisms that might provide parallel signaling path-
ways in subcellular organellar function in the resolution of disease.
We report that a series of small molecules first identified in che-
motherapeutics, (R)-roscovitine [2-(R)-(1-ethyl-2-hydroxyethylamino)-
6-benzylamino-9-isopropylpurine] and its derivatives, restore
microbicidal function to compromised AMs in CF and enhance
function in non-CF cells. The compounds use a G protein-mediated
signaling pathway, which results in the mobilization of transient re-
ceptor potential canonical-6 (TRPC6) calcium-permeable, non-
selective cation channels to the plasma membrane and subsequently
to the phagosomal membrane. Members of the TRP channel family
have been implicated in a number of critical phagocytic functions,
including particle uptake, migration, and reactive oxygen spe-
cies (ROS) production (5, 8–11). Numerous studies (12–15) have
suggested TRP channels as potential targets for the development of
therapies in pulmonary inflammation because of their abundant and
diverse cellular expression throughout the respiratory tree. Although
TRPC6 channels have been previously identified in lung macro-
phages and shown to be up-regulated in COPD, their precise role in
the pathophysiology of the disease is yet to be determined (16).
Perhaps more relevant to our study, a TRPC6-mediated Ca2+ influx
is increased in human CF airway epithelial cells, possibly because
of a functional association between CFTR and TRPC6 that is lost
in CF (17), with unknown consequences. To our knowledge, this
study is the first to associate TRPC6 channels a specific drug-
targeting strategy for the resolution chronic pulmonary infection.
Results
Our goal was to identify compounds that could switch defective
CF macrophages to a state of enhanced microbial killing. The
phagocytic sequence can be divided into three stages: recognition
by and binding of a particle to a surface receptor, internalization
and sequestration of the particle by an actin-dependent process,
and finally, conversion of the phagosomal compartment into a
microbicidal environment. The assay used to screen for innate im-
munity enhancers targeted the final step in the process. Phagosomal
acidification is a prerequisite for efficient bacterial killing (18);
thus, our first screen was for compounds that enhanced phagosomal
acidification upon internalization of bioparticles conjugated to the
pH-sensitive dye pHrodo, as depicted in Fig. 1. Human AMs were
isolated from bronchoalveolar lavage (BAL), plated and cultured
in multiwell plates, and exposed to dye-conjugated lyophilized
Escherichia coli particles for phagocytic uptake (Fig. 1A). The
kinetics of phagosomal uptake and acidification were read in a
plate reader over a period of 3 h, during which time cells continued
to take up particles as well as acidify. In a screen of kinase mod-
ulatory small molecules, (R)-roscovitine and related purines were
identified as candidate compounds for significantly enhancing acid-
ification of phagosomal pH over that observed in untreated cells
(Fig. 1 B and C). Negative controls in the screen included the
V-ATPase inhibitor bafilomycin (Baf) and the potent phospholipase
C inhibitor edelfosine (ET-18-OCH3), previously shown to prevent
phagocytic uptake at the level of actin assembly (19). The N-formyl
peptide, fMLF, which binds to a GPCR, inducing mobilization of
intracellular Ca2+, production of ROS, and chemotaxis in human
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Fig. 1. (R)-roscovitine (rosco) and related derivatives potentiate phagosomal
acidification in human AMs. (A) Schematic of phagocytosis and pHrodo red-
labeled lyophilized E. coli particle acidification. Merged differential interfer-
ence contrast (DIC) and fluorescence images for AMs following a 120- to
200-min loading with the pH sensor pHrodo red-labeled particles. (Scale
bars, 10 μm.) (B1 and B2) Kinetics of acidification for representative com-
pounds in human AMs isolated from BAL. Data in B1 and B2 are repre-
sentative drug response comparisons in AMs obtained from two patients.
(C) Comparative effects of various compounds on relative acidification levels
in human AMs measured in a plate reader after 120 min of bioparticle
feeding. Data summary from two to eight patients for each compound
tested at 10 μM; n = experiments/BAL above each bar. Experimental
populations for all figures are summarized in Table S4. (D) Comparison of
the relative acidification time course obtained from cftr+/+ (wild-type),
cftr−/−, and ΔF508 AMs. (E ) Comparison of acidification time course from
cftr+/+ (wild-type) AMs and cftr−/− AMs in the presence and absence of
20 μM (R)-roscovitine. Experiments done in triplicate were averaged and
presented as means ± SEM; n = mice.














receptor family forms a class of proteins that enhance the innate
immune response and have been proposed as viable targets for
therapeutic drug development (20). (R)-roscovitine (shortened to
roscovitine or “rosco” in the figures), first identified as a cyclin-
dependent kinase (CDK) inhibitor, is also capable of resolving in-
flammation (see ref. 21 for review). The structures and kinase
inhibitory activity of (R)-roscovitine and related molecules identi-
fied in the screen are given in Fig. S1 and Tables S1 and S2. Some
molecules triggering enhanced acidification displayed little or no
kinase inhibitory activity [e.g., M3 (oxo-roscovitine), the major
hepatic (R)-roscovitine biodegradation metabolite, N6-methyl-
roscovitine, “O6-benzyl-roscovitine”], whereas some potent kinase
inhibitors [deaza-finisterine, finisterine A and D, (S)-roscovitine,
olomoucine] were unable to induce acidification, suggesting that
kinase inhibition is unlikely to contribute to the organellar acidifi-
cation properties of (R)-roscovitine and its analogs. The acidification
aspect of the screen was replicated using AMs isolated from cftr+/+
(wild-type), cftr−/−, and ΔF508 mice (Fig. 1D). As in previously
published studies (3, 4), cells either lacking CFTR expression or
expressing the mutant protein showed decreased acidification
compared with cftr+/+ cells. Treatment of cftr−/− cells with (R)-
roscovitine (20 μM) restored acidification to a level not signifi-
cantly different from that observed in cftr+/+ cells (Fig. 1E). Clearly,
a parallel non-CFTR–related acidification pathway exists in cftr−/−
macrophages.
(R)-Roscovitine Rescues Phagosomal Acidification in the Absence of
Functional CFTR Expression: Direct Video Observations. An increase
in total acidification registered in the plate assay could be be-
cause of an increase in particle uptake, an increase in acidifica-
tion in unitary phagosomes, or both. To resolve the relative
contribution of both pathways to the response, we examined the
time course and acidification of individual phagosomes in the
presence of candidate compounds, as well as average particle
uptake per cell in single-cell live video microscopy (Fig. 2A) on
murine cells, where we could manipulate the functional expres-
sion of CFTR and, therefore, phagosomal acidification. These
experiments examined whether: (i) (R)-roscovitine enhanced
phagosomal acidification, particle uptake, or both; and (ii) whether
(R)-roscovitine could rescue the acidification/microbicidal de-
fect in cftr−/− and ΔF508 AMs independent of CFTR expres-
sion. Cells were exposed to zymosan particles doubly conjugated
to the content marker Rhodamine-green and the pH indicator,
pHrodo red, in the presence and absence of (R)-roscovitine
(20 μM). We examined and compared the relative time course of
acidification for all genotypes (Fig. 2B) and compared the rescue
of acidification by (R)-roscovitine in AMs from ΔF508 and cftr−/−
animals (Fig. 2 C and D). The ratio of pHrodo red to rhoda-
mine green fluorescence was converted to pH using an in situ
calibration protocol (Fig. 2E) and used to compare phagosomal
pH data across genotypes in Fig. 2F. (R)-roscovitine enhanced
phagosomal acidification by 1.5 pH units in ΔF508 AMs (pH 5.9
to pH 4.4) and a similar amount in the cftr−/− cells (pH 6.2 to
4.6). No significant change in phagocytic index was observed for
cftr+/+ or ΔF508 AMs (Table S3) following (R)-roscovitine
treatment. The average number of ingested particles per cell
was 2.48 ± 0.07 (n= 551) before and 2.25 ± 0.07 (n= 409) after (R)-
roscovitine treatment for cftr+/+, and 1.93± 0.12 (n = 316) before and
2.10 ± 0.10 (n = 387) after (R)-roscovitine treatment for ΔF508
AMs. Surprisingly, however, in addition to restoring acidifi-
cation, (R)-roscovitine also increased the cellular activation
index (the percentage of phagocytizing cells) in ΔF508 AMs
from 44% to 69%, which was equivalent to that seen in cftr+/+
cells (73%).
(R)-Roscovitine Rescues Bacterial Killing in a CFTR- and Kinase-Inde-
pendent Manner. Given the tight coupling between phagosomal
acidification, host-signaling response, lysosome fusion, and
most importantly, bactericidal activity (3, 22, 23), we examined
whether (R)-roscovitine could restore bacterial killing profiles
in AMs from cftr−/− and ΔF508 CFTR-expressing mice. In these
experiments, cultured AMs were exposed to (R)-roscovitine (20 μM)
for 15–30 min before exposing cells to live, DsRed-expressing
Pseudomonas aeruginosa. Cells were allowed to ingest bacteria
in the continued presence of (R)-roscovitine and were observed
by live-cell video microscopy over a 6-h period for an increase
in fluorescence indicative of bacterial growth, either in the
phagosome or in the cytoplasm following escape from the
phagosome (Fig. 3 A–C). Intracellular bacterial growth as a
function of genotype is compared in Fig. 3 D–F. As expected,
both ΔF508 CFTR and cftr−/− cells showed a reduction in bac-
terial killing, in contrast to wild-type, cftr+/+ cells (Fig. 3D).
(R)-roscovitine significantly rescued bacterial killing in ΔF508
CFTR-expressing cells (Fig. 3E), as well as in cftr−/− cells (Fig. 3F)
to levels similar to that seen in cftr+/+. The CDK kinase-inactive
derivative of (R)-roscovitine, M3, also rescued bacterial killing,
validating that (R)-roscovitine rescue of bacterial killing is
independent of its activity as a kinase inhibitor. Neither (R)-
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Fig. 2. Rescue of phagosomal acidification in murine ΔF508 and cftr−/−
AMs by (R)-roscovitine. (A) A representative murine (ΔF508) cell loaded
with doubly conjugated pHrodo red and rhodamine green zymosan par-
ticles and observed over time. (B) Representative averaged time course
of phagosomal acidification for the three genotypes in the absence of
drug. (C ) Comparative time course of acidification in ΔF508 and (D) cftr−/−
AMs in the presence and absence of 20 μM (R)-roscovitine. Cells were
exposed to drug for 20 min before the addition of zymosan. Data are pre-
sented as means of fluorescence ± SEM and were normalized to fluores-
cence ratio changes observed in untreated control cells in B and to the
(R)-roscovitine–treated cells in C and D. (E ) pHrodo red and rhodamine
green fluorescence ratios (Fred/Fgreen) were calibrated in vivo using a three-
component buffer at the indicated pH values in digitonin-permeabilized
cells. (F ) Summary data using endpoint acidification values obtained in
experiments similar and in addition to those in B–D. The endpoint of each
treatment was determined as the average of last three time points on the
acidification curves. Values for pH were determined by interpolation. The
average pH in phagosomes was: cftr+/+ 4.87 ± 0.2; ΔF508 5.85 ± 0.31 and
4.42 ± 0.07 following (R)-roscovitine treatment; cftr/− 6.2 ± 0.27 and 4.58 ±
0.31 following (R)-roscovitine treatment. Data in B–F expressed as mean ±
SEM; n = particles per cells per mice. Significance level: ***P < 0.001 (two-
way ANOVA).
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revealed either direct bactericidal or bacteria static activity in cell
free assays (Fig. S2).
Patch Clamp Evidence That (R)-Roscovitine Activates a TRPC6 Con-
ductance in AMs Independent of CFTR Expression. Postulating that
(R)-roscovitine might open an unidentified ion channel in the
plasma membrane that would eventually be incorporated into
the phagosomal membrane during the uptake of cargo, we per-
formed whole-cell voltage-clamp experiments on cultured murine
AMs isolated from cftr+/+, cftr−/−, and ΔF508 animals. Experi-
ments were carried out using solutions in which the equilibrium
potential for Cl− was set to −31 mV, allowing us to differentiate
anion from cation selective currents. We monitored current ac-
tivation (Fig. 4A) following a 10-μM (R)-roscovitine exposure and
observed a lag of ∼3–5 min before a current increase was de-
tected at a depolarized potential of +100 mV. This lag suggested
that (R)-roscovitine was not activating channels directly. Drug-
induced current activation while maintaining the whole-cell con-
figuration was observed inconsistently, with variable results in
both activation time course and current amplitude. We attributed
this to the possible loss of a cellular signaling factor integral to the
(R)-roscovitine response via the whole-cell patch pipette. To avoid
possible current rundown (as seen in Fig. 4A), we performed a
population study comparing currents immediately after estab-
lishing the whole-cell configuration in cells across genotypes in
the presence and absence of (R)-roscovitine (Fig. 4 B–D). In the
presence of (R)-roscovitine, AMs of the three genotypes displayed
current activation in the voltage range between −50 and +100
mV, exhibiting a reversal potential of ∼0 mV. Thus, the (R)-
roscovitine sensitive current was: (i) not a Cl− selective conduc-
tance, (ii) was likely a nonselective cation current with significant
inward rectification, and furthermore, (iii) was not dependent on
CFTR expression. (R)-roscovitine–activated currents were similar
in selectivity to those reported (24) for the heterologously
expressed recombinant human TRPC6 channels: nonselective cat-
ion channels that are Ca2+-permeable. Expression of TRPC6 chan-
nels has been reported in human AMs and is known to be elevated
in AMs originating from patients who are smokers and from those
diagnosed with COPD (16). TRPC6 channels are gated through
direct interaction with diacylglycerol (DAG) or its membrane
permeant analog 1-oleoyl-2-acetyl-sn-glycerol (OAG). To explore
the possibility that TRPC6 channels could contribute to the
(R)-roscovitine currents, OAG-induced currents were recorded
from cftr+/+ AMs in standard Na+ and K+ containing bath and
pipette solutions (Fig. 4E). The OAG-induced current voltage
(I-V) relationship was similar to that seen with (R)-roscovitine
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Fig. 3. (R)-Roscovitine rescues bacterial killing defects in cftr−/− and ΔF508
AMs. (A) Representative fluorescence and DIC images of an outlined cell
from a ΔF508 mouse under control conditions and (B) in the presence of
(R)-roscovitine with ingested bacteria at 3 and 8 h. Note: bacteria in B appear
smaller because of lower magnification. (C) Intracellular localization of DsRed-
expressing bacteria was confirmed by 3D reconstruction of confocal z-stacks of
bacterial fluorescence and cellular reflection/backscatter. Orthogonal views inside
one cell are shown in two right panels, confirming intracellular bacterial growth.
(D) Summary data from at least three separate experiments comparing bacterial
growth over time assayed asmean DsRed fluorescence intensity (λ = 607± 20 nm)
and compared across genotypes, (E) in ΔF508 AMs in the presence and absence
of (R)-roscovitine or M3 metabolite, 20 μM, and in (F) in cftr−/− AMs in the
presence and absence of either (R)-roscovitine or M3metabolite, 20 μM. Bacterial
growth in cftr−/− cells compared with growth in ΔF508 AMs was not significantly
different across all time points. Data are presented as means of fluorescence in-
tensities ± SEM. Significance levels determined by one-way ANOVA (*P < 0.05,
**P < 0.01, ***P < 0.001, and ****P < < 0.0001) were determined for six last time
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Fig. 4. (R)-Roscovitine activates TRPC6 conductance in murine AMs. (A) Time
course of whole-cell current activation following treatment with (R)-roscovitine.
Cells were depolarized to +100 mV for 70 ms from a holding potential of
−70 mV at 10-s intervals. Peak current at +100 mV is plotted as a function of time
following (R)-roscovitine addition to the bath. (B) Average current-voltage (I-V)
relationship from wild-type (cftr+/+) cells examined in either control or 20 μM
(R)-roscovitine-containing solutions. (Inset) Representative whole-cell voltage-
clamp recording of AM in the initial absence of drug and subsequent applica-
tion of (R)-roscovitine. (R)-roscovitine-associated whole-cell currents were elicited
during a series of test pulses from −100 to +100 mV in 20-mV increments
from holding potential −40 mV. (C) Average I-V relationship from cftr−/−
cells examined in control solution or solution containing 20 μM (R)-roscovitine,
(D) from ΔF508 cells examined in control or solution containing 20 μM (R)-
roscovitine, and from (E) wild-type (cftr+/+) cells examined in control solution or
in solution containing 100 μM OAG. (Inset) Representative whole-cell voltage-
clamp recording of wild-type AMs in bath solution with and without OAG.
Voltage protocol as in B, above. (F) Plate-reader comparison of the time course
and amplitude of acidification (in arbitrary units) in wild-type AMs as a function
of ingested pHrodo red-conjugated E. coli under control conditions (black), with
20 μM (R)-roscovitine (red), or 100 μM OAG (green). Experiments were per-
formed in triplicate and averaged for each mouse with three mice per treat-
ment. (G) Average I-V relationship recorded from trpc6 −/− cells examined in
control and 20 μM (R)-roscovitine containing bath solution. Solution composi-
tions for bath and pipette in each experimental condition are given in SI Ma-
terials and Methods; number of mice in each experiment is given in Table S4
and indicated in the plots as n = cells per mice.














(Fig. 4 B–D). OAG current density was much larger than that
observed with (R)-roscovitine because of the fact that OAG
activates channels directly, whereas (R)-roscovitine activation
is indirect.
Plasma membrane TRPC6 channels incorporated into the
nascent phagosomal membrane upon particle uptake would facil-
itate cation loss from the lumen, both divalent and monovalent,
augmenting a Cl−-dependent charge-shunt pathway, if present. The
two charge-shunt pathways acting in concert would be expected to
enhance phagosome acidification as seen in the non-CF human
screening data (Fig. 1). Both (R)-roscovitine and OAG significantly
enhanced acidification following bioparticle uptake compared
with control (Fig. 4F). Thus, either a Cl− entry pathway (control)
or the cation efflux [OAG/(R)-roscovitine] pathway could act
alone to shunt V-ATPase–mediated accumulation of positive charge
in the lumen.
To verify that (R)-roscovitine–activated currents were dependent
upon TRPC6 expression, we carried out voltage-clamp experi-
ments on AMs isolated from trpc6−/− animals. As seen in Fig. 4G,
(R)-roscovitine failed to induce current activation in the absence of
TRPC6 expression. The kinase inactive (R)-roscovitine derivative,
M3, showed a similar current-activation profile and was dependent
upon TRPC6 expression as well (Fig. 5 A and B). To further es-
tablish that (R)-roscovitine activates currents indirectly through a
second messenger mechanism active at the internal surface, we
performed cell-attached single-channel experiments in which the
agonists M3 and OAG were added to the bath solution outside the
pipette while currents across the chemically inaccessible patch
membrane were observed. Single-channel open-state probability
was compared under control conditions and in the presence of ei-
ther M3 or OAG (Fig. 5C) with a significant increase observed in
the presence of either agonist (Fig. 5E). Single-channel I-V rela-
tionships for the channels activated in the presence of the bath
applied agonists were similar for M3 and OAG, and the observed
values were consistent with the single-channel conductance of
35 pS reported for TRPC6 in the literature (25, 26) (Fig. 5D). These
data demonstrate that (R)-roscovitine activates channels indirectly
and, furthermore, current activation is dependent upon TRPC6
expression.
Translocation of TRPC6 to the Plasma Membrane upon Exposure to
(R)-Roscovitine and Subsequent Incorporation into Phagosomal
Membranes. We verified that TRPC6 is expressed in murine mac-
rophage-like J774 cells in experiments using an antibody to the
C-terminal cytoplasmic domain, α-hTRPC6796–809, as shown in Fig.
6A and Fig. S4. Significant TRPC6 expression was observed for
murine AMs as well (Fig. S3 B and C). TRPC6 was diffusely dis-
tributed throughout the cytoplasm of resting cells in a clustered
manner suggesting vesicle localization. Although TRPC6 localiza-
tion around phagocytosed zymosan particles can be visualized in
immunocytochemical images, direct proof that TRPC6 is incor-
porated into the phagosomal membrane is seen at high resolution
in the immuno-electron micrographs in Fig. 6 B, 1. Immunogold
labeling of isolated phagosomal membrane fragments from
(R)-roscovitine-treated cells using α-hTRPC6796–809 demonstrated
significant TRPC6 localization over that seen in the control
membranes (Fig. 6 B, 2), indicating clustering and possible tar-
geting to membrane lipid rafts as has been reported for a number
of TRP channels (27–31). Recent data demonstrate that hypoxia in-
duces TRPC6 translocation to caveolin- and sphingolipid-rich mem-
brane rafts in human pulmonary artery smooth-muscle cells (32).
Direct Measurement of Ca2+ Loss from Phagosomes Following Activation
of TRPC6. The ionic content of the phagosome initially reflects that
of the extracellular solution: high in Ca+2, Na+, and Cl−. Activa-
tion of TRPC6 channels in the phagosomal membrane would permit
the efflux of Ca2+ as well as Na+ from the phagosomal lumen down
their electrochemical gradient. To evaluate this hypothesis, we
exposed murine AMs to zymosan particles, which had been satu-
rated in an extracellular solution containing both the fluorescent
Ca2+-sensitive dye, calcein (100 μM), and the protonophore, FCCP
(10 μM). Cells were allowed to take up the zymosan particles and
calcein fluorescence was measured in the absence of TRPC6 acti-
vation. Exposure of the cells to an extracellular solution containing
100 μM La3+ to block the plasma membrane Ca2+-permeable
channels and 100 μM OAG to activate the phagosomal TRPC6



































































































































Fig. 5. The (R)-roscovitine derivative, M3, activates TRPC6 channels in human
and murine AMs using an internal pathway. (A) Peak I-V relationships recorded
from wild-type cells examined in control (n = 5 cells) and in 10 μM M3 con-
taining bath solution (n = 5 cells). M3-stimulated whole-cell currents were eli-
cited during a series of test pulses from −60 to +140 mV in 10-mV increments
from a holding potential of −40 mV. (B) I-V relationships from trpc6−/− cells
examined in control bath solution (n = 5 cells) and in solution containing 10 μM
M3 (n = 5 cells). (C) Representative cell-attached single channel recordings in
human AMs of OAG and M3 elicited currents with corresponding all-points
amplitude histograms. Recordings were taken with 250 nM apamin, 10 μM
Pyr10, 10 μM GlyH 101, and 200 μM DIDS in the pipette solution to block
contaminating channel currents. (D) Single-channel I-V relationships and single-
channel conductance in human AMs detected in the presence of either M3
(10 μM) or OAG (50 μM) outside of the pipette. Cell-attached patches were not
exposed to the agonist in the bath. Mean single-channel amplitude was de-
termined from three patches at each voltage. Calculated single-channel con-
ductance was 36.8 pS for OAG treatment and 35.5 pS for M3 treatment.
(E) Summary of single-channel open-state probabilities recorded with bath
applied OAG or M3 in human AMs as in C. Open-state probabilities were 0.10 ±
0.07 (n = 4 patches) under control conditions, 0.67 ± 0.02 (n = 8 patches) in the
presence of M3, and 0.50 ± 0.08 (n = 5 patches) in the presence of OAG. All
records were obtained at Vp = +80 mV. Significance level: ***P < 0.001 (two-
way ANOVA). Solution composition for bath and pipette in each experimental
condition are given in SI Materials and Methods; number of mice and patient
BAL samples in each experiment is given in Table S4 and indicated in the plots
as n = cells per mice or cells per BAL.
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from wild-type cells (Fig. 6C). As shown in Fig. 6 C, 2, wild-type
cells treated with 20 μM (R)-roscovitine showed an enhanced ki-
netic loss of fluorescence over wild-type. Phagosomes in trpc6−/−
cells showed no loss in Ca2+-dependent calcein fluorescence over
the same time period demonstrating directly the functional role of
TRPC6 activation in phagosomal membranes.
The activation of an OAG-sensitive current, TRPC6, at both
the plasma and phagosomal membranes in the presence of OAG
and (R)-roscovitine would predict that (R)-roscovitine might be
acting indirectly through a GPCR of unknown identity. Such
receptors are plentiful on the macrophage surface and include
formyl peptide, adenosine, and purinergic, as well as chemokine
receptors (33–36). If (R)-roscovitine acts through a GPCR, our
prediction would be that we should see measureable DAG
generation. The expression of a DAG-sensitive CFP/YFP FRET
reporter (DAGR) (37) in J774 cells, allowed us to measure
the kinetics of DAG generation in the response to 50 μM
(R)-roscovitine (working concentration for J774 cells) and 100 μM
OAG (Fig. 7 A and B). In these experiments, OAG acts as a positive
control for DAGR expression and function, as both DAG and its
analog OAG bind to the DAGR. OAG allowed us to estimate the
maximum DAGR response. Both OAG and (R)-roscovitine in-
duced FRET signals, indicative of a (R)-roscovitine–induced GPCR-
mediated response. To further confirm that DAG was generated
through a GPCR pathway, we repeated the experiment in the
presence of pertussis toxin (PTX) (Fig. 7C). The ability of PTX to
inhibit (R)-roscovitine-induced DAG generation in the J774 cells
confirmed the interaction of (R)-roscovitine with an unidentified
GPCR and associated signaling cascade.
(R)-Roscovitine Induces an Increase in the Frequency of Intracellular
Ca2+ Oscillations, Which Is Dependent Upon External Ca2+. If
(R)-roscovitine opens a Ca2+-permeable TRPC6 channel, it follows
that we should observe this interaction as an increase in internal
Ca2+ dependent upon (R)-roscovitine exposure. In Fluo-4AM im-
aging experiments carried out on both murine and human AMs,
exposure to (R)-roscovitine led to increases in the frequency of
spontaneous Ca2+ oscillations (Fig. 8 A and B). Ca2+ oscillations
have been previously described in macrophages, however only in
association with phagocytosis (38, 39). As in the electrophysio-
logical studies, the TRPC6 agonist, OAG, mimicked (R)-rosco-
vitine in increasing Ca2+ spike frequency (Fig. 8C). Oscillations
decayed rapidly following the removal of Ca2+ from the extra-
cellular solution, indicating their dependence upon extracellular
Ca2+ influx. Application of (R)-roscovitine did not rescue the
decline in oscillations after extracellular Ca2+ withdrawal (Fig. S5),
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Fig. 6. Functional TRPC6 expression in AMs and J774 cells. (A1) Confocal im-
munofluorescence images of TRPC6 distribution in representative J774 cells
following zymosan particle phagocytosis (engulfed zymosan particles are
marked with an asterisk). (A2) Following (R)-roscovitine (20 μM) exposure,
TRPC6 colocalizes and surrounds the zymosan particles in a ring-like manner.
(B1) Immunogold labeling of TRPC6 on isolated phagosomal membranes from
nontreated as well as (R)-roscovitine–treated J774 cells. (Scale bar, 100 nm.)
TRPC6 antibody staining was undetectable in trpc6−/− AMs, demonstrating
antibody specificity for TRPC6 (see Fig. S3). (B2) Comparative summary of
immunogold labeling of isolated phagosomal membrane fragments with
equivalent area. Data were analyzed for n = 11 phagosomal fragments (images)
under control conditions and n = 8 fragments for cells pretreated with
(R)-roscovitine before particle uptake. Significance level: **P < 0.01 (Fisher’s
exact test). (C1 and C2) Calcein-monitored Ca2+ changes in phagosomes before
and after (R)-roscovitine or OAG in trpc6+/+ and trpc6−/− AMs: (C1) Merged
confocal fluorescent and DIC images of phagocytosed zymosan particles in
trpc6+/+ (Upper) and trpc6−/− (Lower) AMs. Zymosan particles were preloaded
with calcein (100 μM) and added to cells in bath solution containing 2.5 mM
Ca2+ and the protonophore FCCP (10 μM). Upon stimulation with OAG (100 μM),
there was a rapid loss of Ca2+ from the phagosomes of trpc6+/+cells, but not
from trpc6−/− cells. Calcein fluorescence images were depicted with a heat scale
lookup table andmerged with DIC images and displayed as before (Control) and
after exposure to OAG. (C2) Time course of calcein fluorescence intensity change
in phagosomes from: trpc6−/−, trpc6+/+, and trpc6+/+ cells pretreated with
(R)-roscovitine (20μM) (with indicated numbers of analyzed phagosomes per
cells per mice). Lanthanum (100 μM) was coapplied with OAG to block plas-
malemmal TRPC6 channel activation and preserve intracellular Ca2+ levels;
10 μM FCCP was added to prevent phagosomal acidification in the presence







































Fig. 7. (R)-roscovitine generates DAG via a PTX-sensitive GPCR activation
pathway. (A) Representative cellular expression of the FRET-based CFP/YFP
DAG-reporter in J774 cell fluorescent and DIC images. (Scale bar, 10 μm.)
(B) Time course of (R)-roscovitine–generated DAG production in transfected
J774 cells following exposure to 50 μM (R)-roscovitine (red trace, 12 cells) or
100 μM OAG (green trace, 10 cells) treatment. The gray trace represents
cellular responses in DAG reporter-expressing cells in the absence of drug
treatment (18 cells). (C) (R)-roscovitine (50 μM) failed to elicit DAG pro-
duction in J774 cells treated with PTX (300 ng/mL) overnight. Subsequent
addition of OAG (100 μM) elicited maximum DAG reporter detection and
provided a control for DAGR expression (seven cells). Mean FRET ratio values
are indicated as solid lines and error bars in gray indicate SEM. Number of
the cells and experiments is given in Table S4 and indicated in the plots as
n = cells per experiments.














ing (R)-roscovitine’s indirect activation of TRPC6 Ca2+-permeable
channels through a GPCR signaling pathway. Application of OAG
in the absence of extracellular Ca2+ also failed to enhance Cai os-
cillation frequency (Fig. S5), a finding consistent with their genesis
through TRPC6 activation and subsequent Ca2+ influx.
To further elucidate whether (R)-roscovitine gates a Ca2+-selective
pathway directly from the external surface or indirectly (i.e., at
the cytoplasmic side through a GPCR generating IP3 and DAG
to activate TRPC6), we determined whether the (R)-roscovitine–
enhanced Ca2+ oscillations were dependent upon G-protein
activation. If (R)-roscovitine gates the TRPC6 channel directly
independent of a second messenger-signaling pathway, inhib-
iting G-protein activation with PTX should have no effect on the
frequency or amplitude of Ca2+ oscillations. To test this, cells
were pretreated with PTX (300 ng/mL) for at least 6 h and exam-
ined for (R)-roscovitine enhancement of oscillatory responses. Data
from these experiments, summarized in Fig. 8D, demonstrated that
PTX treatment prevented the (R)-roscovitine–enhanced increase
in Ca2+ oscillation frequency, consistent with (R)-roscovitine acting
through a GPCR. (R)-roscovitine–induced oscillations were de-
pendent upon the expression of TRPC6 failing to enhance Ca2+
oscillation frequency in trpc6−/− cells (Fig. 9).
Direct Measurement of (R)-Roscovitine Induced Exocytotic Insertion
of TRPC6 into the Plasma Membrane Following GPCR Activation in
Human AMs. Quantification of the increase in TRPC6 plasma
membrane localization following (R)-roscovitine treatment was
determined in human AMs using an antibody directed at the
extracellular domain of the protein, α-rTRPC6573–586. Fig. 10A
shows immunocytochemical surface labeling of representative
cells under control conditions and following treatment with
(R)-roscovitine and OAG, both shown to enhance current
activation and Ca+ signaling. The formyl peptide fMLF and 4-
bromo-A23187, both agents known to mobilize Ca2+, also showed
significant enhancement of surface localization (Fig. S6). Quanti-
fication of the enhancement of surface labeling showed significant
increases in surface staining for all compounds over that seen at
steady-state in control cells (Fig. 10B), indicating that any stimulus
capable of generating increases in DAG and Ca2+ might also be
efficient in promoting both phagosomal acidification and killing,
as was seen for fMLF in the initial acidification screen (Fig. 1 B
and C).
The membrane dye FM1-43 has been used extensively to track
exocytosis, endocytosis, and recycling of secretory granules or
vesicles (40). FM1-43 molecules, when present in the extracellular
solution, insert into the plasma membrane and are internalized
during endocytosis. The newly formed vesicles retain dye in their
inner leaflet as well as in the vesicle lumen while in the cyto-
plasmic compartment (Fig. 10C). When stimulated to undergo
exocytosis in a dye-free medium, the vesicles lose their fluo-
rescent content (Fig. 10C). Thus, the exocytotic response is mea-
sured as a decrease in intracellular fluorescence or destaining.
We used this technique to measure the kinetics of the exocytotic
translocation of vesicles upon treatment with either (R)-roscovi-
tine or OAG (Fig. 10D). In the presence of extracellular Ca2+,
both (R)-roscovitine and OAG induced significant destaining of
the AM intracellular compartment over that observed in the
absence of drug. The exocytotic vesicle insertion was dependent
upon external Ca2+, as seen in Fig. 10E. Thus, although this
technique does not allow for the identification of the vesicle-type
or cargo, the correlation between immunocytochemical data (Fig.
10A), electrophysiological current activation, and Ca2+ signaling
support the hypothesis that vesicle fusion is responsible for the
enhancement TRPC6 plasma membrane expression as schemat-
ically represented in Fig. 10F. G protein-mediated activation of
phospholipase C leads to the production of DAG and IP3. DAG
opens Ca2+-permeable, plasmalemmal TRPC6 channels, whereas
IP3 binds to its cognate receptor (IP3R) on the endoplasmic re-
ticulum, triggering release of Ca2+ from internal stores. The con-
sequent rapid rise in cytoplasmic Ca2+ facilitates the translocation











































































































Fig. 8. Intracellular Ca2+ oscillations induced by (R)-roscovitine are de-
pendent upon GPCR activation and mimicked by the DAG analog, OAG, in
human and murine AMs. Experiments were carried out on cultured AMs
using Fluo-4AM as the Ca2+ indicator dye within 2 d after isolation. (A) Rep-
resentative traces showing increases in spontaneous Ca2+ oscillation fre-
quency in human AMs (n = 32 cells, 3 BAL human samples) following exposure
to (R)-roscovitine (50 μM, 15 min). In any given field, only a subpopulation
of cells exhibited oscillatory behavior. In human AMs, 35% exhibited
spontaneous oscillations, whereas 18% of murine AMs showed the same
behavior. The (R)-roscovitine effect was most visible on oscillating cells;
therefore, we confined our analysis to cells with spontaneous oscillations.
There was no obvious morphological difference between oscillating and
nonoscillating cells at rest. (B) Data from murine AMs (n = 24 cells, 3 mice)
are as described for human cells in A. (C) Representative Ca2+ oscillations
and frequency analysis of human AMs in response to application of 50 μM
OAG (n = 16 cells, 2 BAL human samples). (D) Representative Ca2+ oscilla-
tions and frequency analysis of murine macrophages pretreated for 6 h
with 300 nM PTX prior application of 50 μM (R)-roscovitine (n = 61 cells,
2 mice). Significance levels: *P < 0.05, **P < 0.01 (two-way ANOVA). Number
of mice and BAL in each experiment is given in Table S4 and indicated in the








































Fig. 9. (R)-roscovitine–induced increase in internal Ca+2 oscillations is de-
pendent upon TRPC6 expression. (A) Representative Ca2+ oscillations from
trpc6+/+ and trpc6−/− mice before and following exposure to 50 μM
(R)-roscovitine. (B) Summary of the (R)-roscovitine–induced increase in
Ca2+ oscillation frequency comparing first and last 200-s bin time periods
[before and after application of (R)-roscovitine] observed in trpc6+/+ (n = 24
cells, 2 mice) and trpc6−/− cells (n = 36 cells, 2 mice). Significance level: **P <
0.01 (two-way ANOVA).
E6492 | www.pnas.org/cgi/doi/10.1073/pnas.1518966112 Riazanski et al.
These same channels are incorporated into phagosomal membranes
upon bacterial engulfment.
Causal Relationship Between TRPC6 and Phagosome Acidification.
Although it is clear that (R)-roscovitine is causally related to
TRPC6 activation and translocation, the next set of experiments
were directed at determining whether TRPC6 expression is caus-
ally related to enhancement of phagosomal function. If both
CFTR and TRPC6 subserve the same charge-shunt function in
the phagosome, eliminating the expression of one of the channels
would still leave the other to facilitate acidification. Before pro-
ceeding, we carried out experiments to determine if CFTR is
expressed in trpc6−/− cells and vice versa, the results of which are
given in Fig. S7. TRPC6 current was activated by OAG in cftr−/−
cells and expression confirmed by immuno-localization, as seen in
Fig. S7A. Conversely, the cAMP-elevating mixture elicited cur-
rent in the trpc6−/− cells, corroborating positive immunostaining
for CFTR in Fig. S7B.
Given these findings, we used the CFTR inhibitor, CFTRinh172,
to reveal the effect of TRPC6 on acidification in the presence and
absence of (R)-roscovitine. In Fig. 11A we compared the kinetics
and magnitude of phagosomal acidification in wild-type AMs
expressing both CFTR and TRPC6 (cftr+/+/ trpc6+/+). In these
cells, phagosomes containing pHrodo-labeled zymosan particles
failed to acidify in the presence of CFTRinh172 (30 μM). Treat-
ment of the cells with both CFTRinh172 and (R)-roscovitine
showed phagosomal acidification equal to or modestly enhanced
over that observed in untreated control cells, allowing us to
conclude that (R)-roscovitine–induced recovery of phagosomal
function was not dependent upon CFTR activation. Similar ex-
periments performed in trpc6−/− (cftr+/+/trpc6−/−) cells (Fig. 11B)
revealed the unanticipated finding that the absence TRPC6 ex-
pression led to a significant decrease in phagosomal acidification
over that observed in wild-type (cftr+/+/ trpc+/+) cells, indicating
that both anion and cation channels participated in steady-state
phagosomal function. As expected, the trpc6−/− cells were highly
sensitive to CFTRinh172. Finally, (R)-roscovitine in the presence
of CFTRinh172 failed to rescue acidification in the trpc6
−/− cells,
showing a direct and causal relationship between (R)-roscovitine,
TRPC6 expression, and phagosomal acidification.
Discussion
Resolution of chronic pulmonary infection in CF, as well as COPD,
asthma, and tuberculosis, without the use of antimicrobials is a
necessity in a clinical environment faced with increasing bacterial
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Fig. 10. (R)-roscovitine as well as OAG induce exocytotic insertion of TRPC6
channels into the plasma membrane. (A) Human AMs were stained with
α-rTRPC6573–586; cells were treated with either 20 μM (R)-roscovitine or 100 μM
OAG for 15 min at 37 °C before fixation for microscopy. A color gradient
scheme (Rainbow) was used to highlight increased density of TRPC6 surface
labeling following (R)-roscovitine or OAG treatment. A 5 × 5-μm square of
surface staining was highlighted in the Left column of images and expanded in
the Center column to clearly illustrate denser TRPC6 surface labeling. The Right
column depicts an overlay of the TRPC6 immunofluorescence image with its
corresponding DIC image. (B) Comparative summary of surface TRPC6 expres-
sion quantified as mean fluorescence integrated density (area × mean value of
fluorescence intensity) ± SEM. Significance level: **P ≤ 0.01 (Mann–Whitney
rank sum test); cell number in center of the bars. (C) Representative images of
murine AMs, loaded with the membrane marker FM1-43, before (10 s) and
after (1,000 s) application of OAG. Note the significant decrease in cytoplasmic
staining following OAG treatment which reflects the exocytotic release of
FM1-43 into the bath following exocytosis. (D) Comparative time-dependent
changes in cytoplasmic FM1-43 fluorescence following exposure of murine AMs
to 100 μM OAG or 50 μM (R)-roscovitine in 2.5 mM Ca2+-containing bath so-
lution. (E) In Ca2+-free bath solution no significant temporal changes in FM1-43
fluorescence were observed during OAG or (R)-roscovitine treatments. (F) Pro-
posed model for (R)-roscovitine interaction with an as yet unidentified GPCR
and the downstream signaling pathway leading to the exocytotic insertion of
vesicular TRPC6 channels into plasma membrane and their subsequent activa-
tion by DAG. Sample size (n = cells per mice) indicated for each condition and
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Fig. 11. (R)-Roscovitine enhances acidification in CFTRinh172-treated trpc6
+/+
(wild-type) cells but not in the trpc6−/− cells. (A1 and A2) Representative fluo-
rescence-DIC image overlays of trpc6+/+ (wild-type) (A1) and trpc6−/− (A2) AMs
with pHrodo red-labeled zymosan at t = 12 min following loading under three
conditions: DMSO control, 10 μM CFTRinh172, and 10 μM CFTRinh172 plus 20 μM
(R)-roscovitine. (B1) Time course of phagosomal acidification in wild-type AMs
under the following conditions: DMSO control (black trace), 10 μM CFTRinh172
(blue trace), 10 μM CFTRinh172 plus 20 μM (R)-roscovitine (red trace). (B2) Time
course of phagosomal acidification in trpc6−/− AMs under the same conditions
as in B1. Heat scale along the right y axis correlates changes in pHrodo red
zymosan color intensities in the above images with a calibrated pH value range.
Data are displayed as means ± SEM. Sample size (n = phagosomes/cells/mice)
indicated for each condition and detailed in Table S4.














and related metabolites and derivatives rescue phagocytic function
in CF pulmonary macrophages, which is independent of kinase
inhibition and of CFTR expression. Our data, which are modeled
in Fig. S8, are consistent with a mechanism whereby (R)-roscovi-
tine binds to an as yet unidentified GPCR-activating downstream
signaling molecules, including phospholipase C, generating DAG
and IP3, giving rise to Ca
2+ mobilization from external as well as
internal sites. Sequelae include incorporation into and activa-
tion of Ca2+-permeable TRPC6 channels in the plasma, as well
as phagosomal membrane and mobilization and fusion of
endolysosomal vesicles to the maturing phagosome contribut-
ing V-ATPase (Fig. S9), all events leading to luminal phag-
osomal charge neutralization and enhanced acidification, the
prelude to enhanced bacterial killing. Inhibition of (R)-rosco-
vitine action by PTX strongly suggests that it is acting through a
GPCR-mediated pathway. Ligation of selected subsets of
GPCRs is linked to the assembly and activation of NADPH
oxidase and the release of free radicals associated with bacterial
killing in the phagosomes of blood neutrophils (41), and to a
much lesser extent in tissue macrophages (42). Stimulus-in-
duced production of oxidants in tissue macrophages has been
shown to be ∼110-fold less than that observed for blood
phagosomes of blood neutrophils (43). In agreement with these
findings, we were unable to observe an increase in oxidant
(ROS) production in murine AMs challenged with bacteria
following exposure to (R)-roscovitine (Fig. S10B), nor we were
able to see a difference in stimulus-induced generation of ROS
production between the murine AM genotypes, cftr+/+ and cftr−/−,
either in the presence or absence of (R)-roscovitine (Fig. S10). We
have previously shown that murine cftr−/−AMs are not defective in
ROS production but are defective in microbicidal function (3),
strongly suggesting that other microbicidal enzymatic effectors
contributed by lysosomal fusion and activated in the acidic
environment of the phagosome play a significant role in bac-
terial killing. Although both human and murine CF lung mac-
rophages seem to be intrinsically defective in bacterial killing,
there is disagreement in the literature as to whether CFTR
dysfunction impairs the contribution of ROS production to
P. aeruginosa killing (44, 45) and may well be a function of
species and tissue source.
Although we were unable to demonstrate that (R)-roscovitine
acted as a corrector for the trafficking defect in the mutant protein,
as has been previously reported (46), our electrophysiological ex-
periments on isolated cells did demonstrate that (R)-roscovitine
activated a TRPC6 conductance, a response which was absent in
trpc6−/− cells. TRPC6 channels are translocated to the plasma
membrane upon (R)-roscovitine stimulation and appear to remain
in the membrane so long as the stimulus is present. The concept of
TRPC6 mobilization to the plasma membrane as a function of
G-protein receptor activation has been documented for the mus-
carinic receptor in heterologous expression systems (47, 48), as well
as for lysophosphatidylcholine’s inhibition of mouse aortic endo-
thelial cell migration (49), and serves as a template for expression
regulation in the AM. When incorporated into the phagosomal
membrane, TRPC6 would serve as charge-shunt pathway, leading
to the loss of luminal cations and supporting enhanced V-ATPase
proton translocation in the development of the antimicrobial en-
vironment of the phagosomal compartment. Our data demonstrate
that (R)-roscovitine generated DAG could activate plasma mem-
brane resident TRPC6 channels, providing for a local Ca2+ influx
creating a (R)-roscovitine–driven positive feedback loop, support-
ing enhanced translocation of endosomal Ca2+ permeable TRPC6
channels to the plasma membrane or alternatively to the phag-
osomal membrane directly, as well as possibly driving lysosomal
fusion to phagosomes. Increasing expression of TRPC6 at the
plasma membrane would contribute to a microdomain of in-
creased Ca2+ around the phagocytic cup and lead to enhanced in-
corporation of the Ca2+ conductance into the maturing phagosome.
Plasmalemmal TRPC6 incorporated into the phagosomal mem-
brane during particle uptake is then well positioned to act as a
charge-shunt pathway, supporting cation movement out of the
phagosome, amplifying V-ATPase–driven acidification during
the maturation process. In an unanticipated finding, we have
shown that TRPC6 appears to participate in phagosomal acidifi-
cation in the nondrug-treated AM, as well as rescue AM phago-
somal function in drug-treated cells defective in CFTR function.
TRPC6 channels are present at low density in the plasma
membrane of wild-type and CFTR-deficient cells, as seen in Fig.
10 and Fig. S7A. Their activation contributes to a significant
fraction of phagosomal acidification in wild-type cells (Fig. 11B),
which may be because of a regulatory interaction between CFTR
and TRPC6, as seen the in the studies of Tabeling et al. (32) for
pulmonary artery smooth-muscle cells. TRPC6 requires GPCR
activation to generate not only DAG as an agonist for the
channel, but also Ca2+ to induce channel translocation and in-
sertion. If there is a protein–protein interaction between TRPC6
and CFTR, as in the Tabeling et al. studies, which enhances
TRPC6 opening in the wild-type cells, GPCR activation may be
essential for channel opening in the CFTR-deficient cells.
Our data examining the optimization of phagosomal function by
(R)-roscovitine takes advantage of animal models available for the
study of pulmonary inflammation in CF. It serves, however, in a
broader sense as a template for the exploration of novel mecha-
nisms, which might resolve inflammation in a host-directed manner
in a diversity of pulmonary diseases, including tuberculosis, COPD,
and asthma. Knowledge of the signaling and fusion events poten-
tially available to reprogram the phagosome for enhanced micro-
bicidal function is critical for the success of this strategy. The
plethora of GPCRs in resident pulmonary macrophages (36) that
may be linked to ion channel function provides a rich source for
potential therapeutic approaches to macrophage-mediated disease.
This theory is further supported by recent report that TRPML1
channels are similarly involved in charge shunting for large phag-
osomes in bone marrow macrophages (5), and suggests multiple
alternatives to CFTR may exist for mitigating bactericidal defects
in CF, as well as multiple acidification mechanisms in diverse
macrophage lineages.
Materials and Methods
See SI Materials and Methods for details of experimental procedures and
summarized data on sample size (number of particles per cells) and number
of experiments (human or mice) in Table S4.
Animals. All studies detailed herein conform entirely to the principles and
regulations set forth by the Animal Welfare Act, the National Institutes of
Health Guide for the Care and Use of Laboratory Animals (50), and were
approved by the University of Chicago Institutional Animal Care and Use
Committee.
BAL from Humans. All procedures were performed on consenting adults
following a protocol approved by The University of Chicago Institutional
Review Board.
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